First approved TIL therapy scaling toward NSCLC and sarcoma, with confirmatory Phase 3 data the pivot from accelerated to full approval

Bull

Enrollment is nearly complete in the pivotal cohorts and the 25.6% ORR with median duration of response not reached at 25.4 months of follow-up provides a compelling efficacy signal; if the sBLA is accepted and accelerated approval is granted, lifileucel would enter the NSCLC market as the first approved TIL therapy in that indication, opening a patient population many times larger than melanoma and serving as a platform-validating inflection point that could substantially re-rate the stock.

Bear

The FDA could determine that the single-arm response rate data are insufficient for accelerated approval in a heavily pre-treated NSCLC population where multiple approved checkpoint inhibitors and targeted therapies already exist, or may require a randomized confirmatory cohort prior to granting approval; additionally, the complex logistics and cost of TIL therapy manufacturing could raise concerns about benefit-risk in a population with shorter expected survival and less robust tumor-infiltrating lymphocyte yield than melanoma.